Dalbavancin Study Results To Be Presented In Three Posters At The 53rd Annual ICAAC Meeting

CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, September 10-13, 2013. The trials were conducted via a Special Protocol Assessment based on the FDA's Draft Guidance for Developing Drugs for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dalbavancin is under investigation for the treatment of ABSSSI caused by susceptible Gram-positive microorganisms. These data will be used to support the company's anticipated submission of a New Drug Application to the U.S. Food and Drug Administration at the end of September 2013.

In addition, R.M. Alden Research Lab will present in vitro data regarding the activity of dalbavancin against isolates obtained from osteomyelitis infections. This research was supported by a grant from Durata Therapeutics.

The following posters will be presented:
Tuesday, September 10, 2013
12 p.m. - 2 p.m.
Title: DISCOVER 1: A Randomized, Double-blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: H. W. Boucher 1, M. Wilcox 2, G. H. Talbot 3, A. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Tufts Med. Ctr., Boston, MA,  2Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-201
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: DISCOVER 2: A Randomized, Double-Blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: M. Wilcox 1, H. W. Boucher 2, G. H. Talbot 3, A. F. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  2Tufts Med. Ctr., Boston, MA,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-202
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: In Vitro Activity of Dalbavancin Against Consecutive Isolates of Staphylococcus Species Recovered from Osteomyelitis Infections
Authors: D. M. Citron, E. J. Goldstein (R.M. Alden Res. Lab., Culver City, CA)
Poster #: E-140

The abstracts are currently available on the ICAAC website at www.icaac.org and copies of the posters will be available following the ICAAC meeting at www.duratatherapeutics.com

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. 

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan